drugset / Trial / NCT03166085
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to decide the best dose of the study drug, PU-H71, that can be given in combination with the standard chemotherapy drug, nab-paclitaxel (Abraxane).
Timeline
- Start
- 2017-05-23
- Primary completion
- 2021-12-14
- Completion
- 2021-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | PU-H71 | Small molecule | — | Intravenous |